From opium to fentanyl: rural life, politics and crime in Mexico

 

efdapf2bc.jpg

Drugs, International Challenges n° 14, OFDT, 9 p.
December 2021

Unlike in other parts of the world, poppy cultivation and opium use are recent phenomena in Mexican history. Their development during the 20th century was the product of social and political factors which must be studied in order to understand Mexico's current position in the international market for illegal opioids, as well as the turning point which seems to have taken place in recent years with the emergence of a new type of substance: illegal fentanyls.

In order to understand how the illegal poppy economy in Mexico was built and the consequences of its decline on the stakeholders involved, this 14th issue of Drugs, international challenges proposes to place the development of poppy cultivation and heroin production in Mexico in its geographical and historical context, before exploring, through an analysis of descriptive statistics and secondary field sources, the impact of recent fluctuations in the heroin market on poppy cultivators.

Author: Paul Frissard Martínez (Noria Research)

Download the PDF file (765 Ko)

 

 

 

 

 

 

 

 

 

 

 

Drugs in Europe


2021 EMCDDA European Drug Report

COVID-19
How is the COVID-19 pandemic affecting drug use, supply and services?
Drug use and harms
What are the health costs of drug use in Europe today?
Drug markets
What do the latest data tell us about drug production and trafficking trends?

These and other questions are explored in the 2021 European Drug Report, our annual overview of the drug situation in Europe.

  Statistical Bulletin 2021

The annual Statistical Bulletin contains the most recent available data on the drug situation in Europe provided by the Member States. These datasets underpin the analysis presented in the European Drug Report. All data may be viewed interactively on screen and downloaded in Excel format..

The European Union and the drug phenomenon

miniFAQDrugsEurope.jpgThe European Union & the drug phenomenon : Frequently asked questions, joint publication between the EMCDDA and the European Commission, october 2010, 12 p.